ADRX ADARx Pharmaceuticals, Inc.

Fundamentals / CIK 0001802369 / USD

ADARx Pharmaceuticals, Inc. reported $929.1M in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ADRX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for ADRX.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Revenue $2.22M -- -- $1.55M -- --
Research & Development $26.71M -- -- $19.42M -- --
Selling, General & Admin $7.68M -- -- $5.15M -- --
Total Operating Expenses $34.39M -- -- $24.56M -- --
Operating Income -$32.18M -- -- -$23.01M -- --
EBITDA -$31.88M -- -- -$22.71M -- --
Interest Income $3.48M -- -- $4.62M -- --
Net Income -$28.12M -$25.76M -$22.67M -$17.88M -$18.09M -$15.55M
Basic EPS -$1.74 -- -- -$1.85 -- --
Diluted EPS -$1.74 -- -- -$1.85 -- --
Basic Shares Outstanding 16.1M -- -- 9.7M -- --
Diluted Shares Outstanding 16.1M -- -- 9.7M -- --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for ADRX.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2025-12-31
Cash & Cash Equivalents $570.6M $66.52M
Short-Term Investments $330.4M $413.5M
Cash & Short-Term Investments $901.0M $480.0M
Total Current Assets $918.5M $493.4M
Property, Plant & Equipment, Net $4.40M $4.73M
Other Non-Current Assets $100K $2.21M
Total Non-Current Assets $10.55M $14.28M
Total Assets $929.1M $507.7M
Accounts Payable $9.35M $5.84M
Deferred Revenue (Current) $20.92M $16.56M
Total Current Liabilities $43.57M $30.48M
Total Non-Current Liabilities $311.1M $321.8M
Total Liabilities $354.7M $352.3M
Total Debt (incl. Leases) $6.46M $7.74M
Common Stock $11K $0
Retained Earnings -$297.2M -$220.7M
Accumulated Other Comp. Income -$2.15M $1.96M
Total Stockholders' Equity $574.4M -$202.3M
Total Equity $574.4M -$202.3M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for ADRX.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Net Income -$28.12M -$25.76M -$22.67M -$17.88M -$18.09M -$15.55M
Depreciation & Amortization $300K -- -- $300K -- --
Stock-Based Compensation $1.9K -- -- $1.4K -- --

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for ADRX.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Current Ratio 21.08x -- -- -- -- --
Quick Ratio 20.68x -- -- -- -- --
Debt to Equity 0.01x -- -- -- -- --
Revenue Growth (YoY) +42.6% -- -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0001802369) · from March 31, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:26 UTC · Open in terminal